AU2004293182B2 - Compositions comprising polypeptides - Google Patents

Compositions comprising polypeptides Download PDF

Info

Publication number
AU2004293182B2
AU2004293182B2 AU2004293182A AU2004293182A AU2004293182B2 AU 2004293182 B2 AU2004293182 B2 AU 2004293182B2 AU 2004293182 A AU2004293182 A AU 2004293182A AU 2004293182 A AU2004293182 A AU 2004293182A AU 2004293182 B2 AU2004293182 B2 AU 2004293182B2
Authority
AU
Australia
Prior art keywords
polypeptide
multimeric
composition
antigen
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004293182A
Other languages
English (en)
Other versions
AU2004293182A1 (en
Inventor
Patrick Baeuerle
Frank Hanakam
Robert Hofmeister
Christian Itin
Nadja Prang
Thomas Urbig
Andreas Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of AU2004293182A1 publication Critical patent/AU2004293182A1/en
Application granted granted Critical
Publication of AU2004293182B2 publication Critical patent/AU2004293182B2/en
Assigned to AMGEN RESEARCH (MUNICH) GMBH reassignment AMGEN RESEARCH (MUNICH) GMBH Request to Amend Deed and Register Assignors: MICROMET AG
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004293182A 2003-11-28 2004-11-26 Compositions comprising polypeptides Expired AU2004293182B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03027511.9 2003-11-28
EP03027511 2003-11-28
PCT/EP2004/013445 WO2005052004A2 (en) 2003-11-28 2004-11-26 Compositions comprising polypeptides

Publications (2)

Publication Number Publication Date
AU2004293182A1 AU2004293182A1 (en) 2005-06-09
AU2004293182B2 true AU2004293182B2 (en) 2010-02-18

Family

ID=34626385

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004293182A Expired AU2004293182B2 (en) 2003-11-28 2004-11-26 Compositions comprising polypeptides

Country Status (18)

Country Link
US (1) US10000574B2 (cg-RX-API-DMAC7.html)
EP (2) EP2186527A1 (cg-RX-API-DMAC7.html)
AT (1) ATE459374T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004293182B2 (cg-RX-API-DMAC7.html)
BE (1) BE2016C023I2 (cg-RX-API-DMAC7.html)
CA (1) CA2544532C (cg-RX-API-DMAC7.html)
CY (2) CY1110689T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004025840D1 (cg-RX-API-DMAC7.html)
DK (1) DK1691833T3 (cg-RX-API-DMAC7.html)
ES (1) ES2341252T3 (cg-RX-API-DMAC7.html)
FR (1) FR16C1000I2 (cg-RX-API-DMAC7.html)
HU (1) HUS1600019I1 (cg-RX-API-DMAC7.html)
LU (1) LU93067I2 (cg-RX-API-DMAC7.html)
NL (1) NL300807I2 (cg-RX-API-DMAC7.html)
PL (1) PL1691833T3 (cg-RX-API-DMAC7.html)
PT (1) PT1691833E (cg-RX-API-DMAC7.html)
SI (1) SI1691833T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005052004A2 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
CA2662340C (en) * 2006-09-08 2016-08-02 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US9308257B2 (en) * 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
LT3018145T (lt) 2010-10-27 2018-05-10 Amgen Research (Munich) Gmbh Priemonės ir būdai dlbcl gydymui
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
RU2632647C2 (ru) 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
AU2014364593A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
SG10201808519VA (en) 2013-12-17 2018-10-30 Genentech Inc Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
RU2718692C2 (ru) 2014-05-29 2020-04-13 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
MX384534B (es) 2014-11-05 2025-03-14 Genentech Inc Metodos de produccion de proteinas de cadena doble en bacterias.
EP3753948A1 (en) 2014-11-05 2020-12-23 Genentech, Inc. Methods of producing two chain proteins in bacteria
JP2018508481A (ja) 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体
HK1255200A1 (zh) 2015-05-29 2019-08-09 F. Hoffmann-La Roche Ag 癌症中pd-l1启动子甲基化
EP3310815A1 (en) 2015-06-17 2018-04-25 F. Hoffmann-La Roche AG Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3-BINDING POLYPEPTIDES
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
FI3377103T4 (fi) 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
ES2901794T3 (es) 2015-12-09 2022-03-23 Hoffmann La Roche Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
AU2018276419A1 (en) 2016-06-02 2019-10-17 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
EP3554542A1 (en) 2016-12-19 2019-10-23 H. Hoffnabb-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
WO2018114748A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
AU2018359506A1 (en) 2017-11-01 2020-04-23 F. Hoffmann-La Roche Ag Combination therapy with targeted OX40 agonists
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
PL3765489T3 (pl) 2018-03-13 2025-02-10 F. Hoffmann-La Roche Ag Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
CA3102562A1 (en) * 2018-06-07 2019-12-12 Cullinan Management, Inc. Multi-specific binding proteins and methods of use thereof
AU2019342133B8 (en) 2018-09-21 2025-08-07 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
SG11202104104VA (en) 2018-11-05 2021-05-28 Genentech Inc Methods of producing two chain proteins in prokaryotic host cells
US20220204620A1 (en) 2019-04-30 2022-06-30 Amgen Research (Munich) Gmbh Means and methods for treating burkitt lymphoma or leukemia
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
KR102878895B1 (ko) 2019-05-21 2025-10-31 노파르티스 아게 Cd19 결합 분자 및 이의 용도
US12428480B2 (en) 2019-12-11 2025-09-30 Cullinan Therapeutics, Inc. Anti-CD19 antibodies and multi-specific binding proteins
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
KR102453073B1 (ko) 2020-08-14 2022-10-11 건국대학교 글로컬산학협력단 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
TW202304524A (zh) 2021-04-10 2023-02-01 美商普方生物製藥美國公司 Folr1結合劑、其結合物及使用方法
AU2022262644A1 (en) 2021-04-23 2023-11-09 Genmab A/S Anti-cd70 antibodies, conjugates thereof and methods of using the same
EP4083061A1 (en) * 2021-04-30 2022-11-02 Kilometro Rosso SPA Fusion proteins and use thereof in the treatment of membranous nephropathy
WO2022228706A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
KR20240164782A (ko) 2022-03-23 2024-11-20 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체와 화학요법의 병용 치료
CA3255366A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
JP2025541593A (ja) 2022-11-03 2025-12-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ１９／抗ｃｄ２８二重特異性抗体による併用療法
WO2024243423A1 (en) 2023-05-24 2024-11-28 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025222129A2 (en) 2024-04-19 2025-10-23 Mozart Therapeutics, Inc. Engineered cytokines and targeted cytokine delivery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054440A1 (en) * 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
JPH06508985A (ja) 1991-02-27 1994-10-13 クリエイティブ　バイオモレキュルズ　インコーポレイテッド 富セリンペプチドリンカー
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US20020142964A1 (en) * 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054440A1 (en) * 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
EP1348715A2 (en) * 1998-04-21 2003-10-01 Micromet AG CD19xCD3 specific polypeptides and uses thereof
US7112324B1 (en) * 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Jager, M. et al., European Journal of Canber, Vol.37, September 2001, page S60 *
Loeffler A et al. Leukemia, Vol 17, No.5, May 2003. pages 900-909 *
Loeffler, A et al., Blood, Vol.95, No.6, Match 2000, pages 2098-2103 *
Maletz, K International Hourna lof Canber, Vol.93, No.3, August 2001, pages 409-416 *
Schoberth, A et al., European Journal of Canber, Vol.37, September 2001, page S51 *

Also Published As

Publication number Publication date
DE602004025840D1 (de) 2010-04-15
PL1691833T3 (pl) 2010-08-31
CY2016010I1 (el) 2016-08-31
NL300807I2 (cg-RX-API-DMAC7.html) 2016-10-13
HUS1600019I1 (hu) 2016-06-28
DK1691833T3 (da) 2010-05-03
AU2004293182A1 (en) 2005-06-09
BE2016C023I2 (cg-RX-API-DMAC7.html) 2023-12-18
CA2544532C (en) 2015-06-16
SI1691833T1 (sl) 2010-06-30
CA2544532A1 (en) 2005-06-09
US20070249529A1 (en) 2007-10-25
LU93067I2 (fr) 2016-07-11
US10000574B2 (en) 2018-06-19
EP2186527A1 (en) 2010-05-19
EP1691833B1 (en) 2010-03-03
WO2005052004A3 (en) 2006-03-09
ES2341252T3 (es) 2010-06-17
FR16C1000I2 (fr) 2017-02-03
PT1691833E (pt) 2010-06-08
CY2016010I2 (el) 2016-08-31
FR16C1000I1 (cg-RX-API-DMAC7.html) 2016-06-24
WO2005052004A2 (en) 2005-06-09
ATE459374T1 (de) 2010-03-15
EP1691833A2 (en) 2006-08-23
CY1110689T1 (el) 2015-06-10

Similar Documents

Publication Publication Date Title
AU2004293182B2 (en) Compositions comprising polypeptides
US11572415B2 (en) Multivalent FV antibodies
AU2015249006B2 (en) Trifunctional antigen-binding molecule
JP7262597B2 (ja) 二重特異性抗体及びその作製方法と使用
Morris et al. Development and characterization of recombinant human Fc: OX40L fusion protein linked via a coiled-coil trimerization domain
CA3114451A1 (en) T cell receptor for identifying ssx2 antigen
CN117986384A (zh) 与il-12和il-18的基于il-15的融合物
RS61590B1 (sr) Monoklonsko antitelo protiv ctla4 ili njegov antigen-vezujući fragment, medicinska kompozicija i upotreba
KR20170041697A (ko) 이중특이적 cd33 및 cd3 결합 단백질
CA3108466A1 (en) T cell receptor for identifying afp antigen
CN116635071A (zh) 抗tspan8-抗cd3双特异性抗体和抗tspan8抗体
CN108840932A (zh) 一种pd-1特异性抗体及其抗肿瘤应用
KR20230030587A (ko) Nk 세포와 항체의 결합을 안정화시키는 방법, 및 그 이용
CN109422814B (zh) 一种抗La/SSB嵌合体抗原修饰的NK细胞、其制备方法及其应用
CN118725131A (zh) 抗tnfr2/抗pd-1或ctla-4双特异性抗体及其应用
KR20240021289A (ko) Bcma 및 cd3에 결합하는 이중특이성 항체 및 그 제조 방법과 응용
CN110872356B (zh) 双特异性抗体及其使用方法
CN113646433A (zh) 靶向抗TNF-α抗体的组合物和方法
CN111484554B (zh) 一种靶向4-1bb的肿瘤抑制性抗体及其应用
KR101260421B1 (ko) Ｃｔｌａ４ 및 ｉｌ２１ｒ 을 포함하는 융합 단백질 및 이를 포함하는 관절염 예방 및 치료용 조성물
JP2025539875A (ja) 融合ポリペプチドおよびその使用
RU2785766C9 (ru) Мультивалентные fv-антитела
RU2785766C2 (ru) Мультивалентные fv-антитела
CN120441708A (zh) 一种靶向cd3和l1cam的双特异性抗体及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ AMGEN RESEARCH (MUNICH) GMBH .

MK14 Patent ceased section 143(a) (annual fees not paid) or expired